Celsion (NASDAQ:CLSN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Celsion (NASDAQ:CLSN – Get Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright assumed coverage on shares of Celsion in a research report on Wednesday, April 13th. They issued a “buy” rating and a $16.00 price objective for the company.

CLSN opened at $3.33 on Tuesday. The company’s fifty day moving average price is $5.08 and its two-hundred day moving average price is $8.54. The company has a market cap of $19.22 million, a price-to-earnings ratio of -0.85 and a beta of 2.11. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 0.10. Celsion has a 1-year low of $3.26 and a 1-year high of $23.25.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new position in Celsion in the 2nd quarter worth about $228,000. Geode Capital Management LLC grew its stake in shares of Celsion by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 756,885 shares of the biotechnology company’s stock valued at $699,000 after acquiring an additional 54,785 shares during the period. Morgan Stanley boosted its stake in Celsion by 44.6% in the 3rd quarter. Morgan Stanley now owns 2,332,078 shares of the biotechnology company’s stock worth $2,156,000 after purchasing an additional 719,758 shares during the period. Two Sigma Advisers LP bought a new position in Celsion in the 3rd quarter worth approximately $68,000. Finally, Jane Street Group LLC raised its holdings in shares of Celsion by 181.8% during the 3rd quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 23,261 shares in the last quarter. 10.75% of the stock is owned by hedge funds and other institutional investors.

About Celsion (Get Rating)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

Featured Articles